In a significant development for cancer research, Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical company renowned for its innovative medicines in oncology, cardiovascular and metabolic diseases, autoimmune disorders, ophthalmology, and other major diseases, has announced the presentation of preclinical data on multiple novel bispecific antibodies and antibody-drug conjugates (ADCs) from its oncology pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024.

This research, involving cutting-edge bispecific antibodies and ADCs, aims to introduce first-in-class treatments for various solid tumors, marking a significant stride in cancer therapy. The presentations, focusing on Innovent’s innovative approaches in drug development, were led by Dr. Kaijie He and Dr. Huizhong Xiong, showcasing the company’s dedication to advancing cancer treatment through groundbreaking research.

One of the highlights from the AACR meeting is IBI3001, a potential first-in-class bispecific ADC targeting B7-H3 and EGFR. Developed using Innovent’s SYNtecanE® platform, IBI3001 demonstrated strong anti-tumor efficacy across multiple solid tumors, enhanced EGFR signaling blockade, and a well-tolerated profile, making it a promising candidate for further clinical development.

Additionally, Innovent introduced IBI334, an afucosylated bispecific antibody against B7-H3 and EGFR constructed with Innovent’s proprietary Innobody platform. IBI334 exhibited potent pre-clinical efficacy and a favorable safety profile, positioning it as a valuable addition to cancer treatment options, currently under clinical evaluation.

The discovery of IBI343, a site-specific glycan-conjugated anti-Claudin18.2 ADC using Synaffix’s GlycoConnect® technology, also stands out. IBI343 showed significant in vitro and in vivo efficacy against Claudin 18.2-positive tumors, underlining the potential of glycan-based conjugation technology in enhancing ADC stability and safety.

In the field of immune-stimulating antibody conjugates (ISACs), a novel TROP2-targeted ISAC demonstrated potent anti-tumoral activity and acceptable safety, potentially benefiting patients with TROP2+ tumors. This innovative approach aims to balance efficacy and safety, a common challenge in the development of ISACs.

Moreover, the research on a tumor-targeted CD28 bispecific antibody, IAR038, revealed optimized potency and robust anti-tumoral activity with stringent CD3-dependence, suggesting a promising avenue for improving safety and therapeutic window in cancer treatment.

Dr. Kaijie He and Dr. Huizhong Xiong’s statements underscore Innovent’s commitment to leveraging its expertise and technology platforms to develop safer and more effective cancer treatments. The company’s presentations at the AACR 2024 Annual Meeting highlight the potential of its novel anti-cancer drugs and their impact on the future of oncology.

Innovent Biologics’ dedication to innovation in cancer therapy is reflected in its comprehensive approach to drug development, from meticulous molecule design to optimization, aiming to broaden the therapeutic windows and enhance patient outcomes.

As these novel treatments progress through clinical trials, the hope is that they will offer new, effective options for combating cancer.

Innovent Biologics’ presentation at the AACR Annual Meeting 2024 represents a pivotal moment in the fight against cancer. The preclinical data showcases not only the breadth of Innovent’s research but also the depth of its commitment to addressing the complex challenges of cancer therapy. By pushing the boundaries of biotechnology and pharmacology, Innovent is at the forefront of developing innovative treatments that promise to improve the lives of patients worldwide.

  AACR Annual Meeting 2024, antibody-drug conjugates, bispecific antibodies, cancer research, cancer therapy, CD28 bispecific antibody, IBI3001, IBI334, IBI343, innovative cancer treatments, Innovent Biologics, Oncology, preclinical data, Solid tumors, TROP2 ISAC